Clinical trial IJB_2732
A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/1b |
| Academic trial | Non |
| Sponsor | Lilly |
| EudraCT Identifier | 2017-002693-39 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03343613 |
| Inclusion criteria | Metastatic Biopsy mandatory |
| Last update |